📊 EdTech Rallies, FDA Lifts Biopharma, and Copper Makes Noise

Good Morning Investors,

Friday wrapped with sharp swings, heavy volume, and a few names grabbing headlines for all the right reasons. Chegg $CHGG ( ▼ 4.86% ) led the rebound, joined by Prime Medicine $PRME ( ▲ 15.0% ) and ProKidney $PROK ( ▼ 5.2% ) as biopharma names clawed back lost ground.

Phathom Pharmaceuticals $PHAT ( ▼ 4.4% ) lit up the tape after winning 10 years of FDA exclusivity for its acid-blocker, while Taseko Mines $TGB ( ▼ 6.67% ) caught fire on news of a landmark agreement tied to its New Prosperity project.

But not every story ended bullish. Petco $WOOF ( ▲ 8.23% ) slipped on lackluster earnings, and Accuray $ARAY ( ▼ 0.81% ) fell after a refinancing move left investors unconvinced.

Here’s what moved before the weekend. 👇

Matthias Schneider
Editor at Analytica Investor

↑ ↓ 1-day change
Market data: Friday’s market close

The small-cap market enjoyed a buoyant performance with the Russell 2000 growing by 1.4%. The news was generally positive with strong job reports stimulating a boost in the market. The S&P/TSX Venture Composite Index also experienced growth, rising by 0.6%, as did the NASDAQ Composite which saw a 1.2% gain.

Several particular sectors proved themselves major performers. The energy sector performed remarkably with the S&P 500 Energy index posting an uplift of 1.9%. Similarly, the biotechnology industry experienced a boost with the NASDAQ Biotechnology index marking a rise of 1.7%. The positive market sentiment extended to commodities as the S&P GSCI Index experienced a 0.8% gain.

The optimistic jobs report from Seeking Alpha played a significant role in the market's performance. Expectations for US-China trade talks, as reported by Bloomberg Markets and Finance, also contributed to the positive trend. Other significant news included President Trump's call for a rate cut and speculations about the impact of tariffs on the market as reported by CNBC.

In the biotechnology realm, investing in GLP-1 pills and cancer drugs is in focus amid supply chain uncertainty according to Yahoo Finance.

In summary, the small-cap market conveyed a bullish sentiment with an upturn across major indices, boosted by encouraging sector performances and guided by positive news and developments.

A Word From Our Partner

The Daily Newsletter for Intellectually Curious Readers

Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.

Join for free today!

📈 Biggest Gainers 

• NET Power Inc. ($NPWR NYSE) - 35%: 
  Market Cap: 226,962,548
  
  Operating from Durham, North Carolina, it invents, develops, and licenses clean energy power generation technology since 2010.
  
  The recent 35% drop in the stock's value was a direct result of numerous public relations releases announcing class action lawsuits against the firm, which eroded investor confidence and incited widespread selling. (1, 2, 3,)

• Chegg, Inc. ($CHGG NYSE) - 35%:
  Market Cap: 173,709,100
  
  Operates a direct-to-student learning platform offering textbooks, subscription services, and digital products to support academic and career development.

• Neumora Therapeutics, Inc. Common Stock ($NMRA NASDAQ) - 26%:
  Market Cap: 164,982,878
  
  A clinical-stage biopharmaceutical company specializing in the development of treatments for various brain diseases and neuropsychiatric disorders.

• Prime Medicine, Inc. ($PRME NASDAQ) - 24%: 
  Market Cap: 221,887,621
  
  A biotech firm delivering genetic therapies via gene editing technology, developing Prime Editors and headquartered in Cambridge, Massachusetts.

• ProKidney Corp. ($PROK NASDAQ) - 24%: 
  Market Cap: 286,141,217
  
  A clinical-stage biotech firm, it develops cellular therapy candidates targeting diabetic kidney disease and urinary tract anomalies in its North Carolina headquarters.

• Canopy Growth Corporation ($CGC NASDAQ) - 24%: 
  Market Cap: 353,037,298
  
  Engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical use, primarily in Canada, the US, and Germany.
  
  The flurry of press releases around class action lawsuits and securities fraud allegations have intertwined with and directly influenced the recent 24% drop in the stock's price. (1, 2, 3,)

• MacroGenics, Inc. ($MGNX NASDAQ) - 23%:
  Market Cap: 112,300,734
  
  Specializes in developing and commercializing antibody-based therapeutics to treat cancer, with an extensive pipeline of immuno-oncology product candidates.
  
  The presentation at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 significantly influenced the recent 23% surge in the stock's price. (1)

• Brooge Energy Limited ($BROG NASDAQ) - 22%:
  Market Cap: 207,843,928
  
  Provides oil storage and related services including the capacity for heating and blending of various petroleum products in Fujairah, UAE.

• Fate Therapeutics, Inc. ($FATE NASDAQ) - 19%:
  Market Cap: 183,412,800
  
  A clinical-stage biopharmaceutical company specializing in developing programmed cellular immunotherapies for cancer and immune disorders worldwide.

📉 Biggest Losers

• Petco Health and Wellness Company, Inc. ($WOOF NASDAQ) - -23%: 
  Market Cap: 769,630,652
  
  Specializes in pet health and wellness services, including veterinary care, grooming, training, and retail of pet supplies, in approximately 1,500 locations.
  
  The release of disappointing first quarter 2025 financial results led to a notable 23% drop in the stock's recent price. (1)

• Next Technology Holding Inc. ($NXTT NASDAQ) - -16%:
  Market Cap: 593,320,400
  
  Offers technical services, AI systems, multi-channel data analysis, and varied payment systems primarily in China through its social e-commerce platform.

• Accuray Incorporated ($ARAY NASDAQ) - -15%:
  Market Cap: 132,886,770
  
  Designs, manufactures, and sells radiosurgery and radiation therapy systems for tumor treatment worldwide, along with offering related services and support.
  
  The announcement of the exchange of convertible notes and refinancing of existing credit facilities led to a 15% decline in the stock price. (1)

• XChange TEC.INC ($XHG NASDAQ) - -11%: 
  Market Cap: 225,126,726
  
  Engages in the professional insurance agency business in China, providing various insurance products and SaaS services, primarily to individual end consumers.

🚀 Biggest Movers

• Opendoor Technologies Inc. ($OPEN NASDAQ) - 53,182,185 shares traded with an average volume of 62,023,426 (3%):
  Market Cap: 495,504,181
  
  This digital real estate platform enables US consumers to buy and sell homes online, additionally offering title insurance and escrow services.
  
  The recent fluctuation in the stock's price was significantly influenced by the announcement of a preliminary proxy filing seeking approval for a discretionary reverse stock split. (1)

• Phathom Pharmaceuticals, Inc. ($PHAT NASDAQ) - 52,639,543 shares traded with an average volume of 1,629,863 (90%): 
  Market Cap: 622,741,772
  
  Specializes in developing and commercializing treatments for gastrointestinal diseases, holding rights to vonoprazan, a stomach acid-blocking drug, in the US, Europe, and Canada.
  
  The recent surge in stock trading volume and price was a direct result of the positive FDA decision recognizing 10 years of regulatory exclusivity for VOQUEZNA® (vonoprazan) tablets, underpinning heightened investor confidence and interest. (1)

• Taseko Mines Limited ($TGB AMEX) - 47,288,046 shares traded with an average volume of 13,872,723 (18%):
  Market Cap: 966,577,500
  
  Acquires, develops and operates mineral properties, exploring for copper, molybdenum, gold, niobium, and silver in Canada and Arizona.
  
  The historic agreement reached with Tŝilhqot'in Nation and the Province of BC concerning the New Prosperity Project significantly influenced the recent surge in share trades, increasing trading volume by 18%. (1)

Post Of The Day

💵 Recent Earnings

G-III Apparel Group $GIII stylishly beat estimates yesterday, stitching up a fabric of success with 1% revenue increase and a trend-defying 58% surprise in EPS.

Reporting 2025-06-07:

G-III Apparel Group, Ltd. $GIII ( ▲ 2.38% ) - Designs, sources, and markets various types of apparel and accessories worldwide, operating through wholesale and retail channels, both physically and online.

• Revenue: 583,609,000 vs est. 580,366,380 (1%)
• EPS: 0.19 vs est. 0.12 (58%)
• Market Cap: 974,527,681
• Sector, Industry: Consumer Cyclical, Apparel - Manufacturers

👀 Stocks To Add To Your Watchlist

$DPRO ( ▲ 28.02% ) · NASDAQ Capital Market — Draganfly Inc. 
Industrials/Aerospace & Defense
YTD: -27.737%
Market Cap: $16,138,445

DPRO has shown a remarkable rally with a last-day percentage change of +22.22% on NASDAQ, closing at $2.97. This surge reflects strong market enthusiasm following recent announcements including the partial exercise of an over-allotment option, key deliveries to a major U.S. defense contractor, and strategic board appointments.

Given the company's innovative drone solutions in critical sectors, alongside significant advancements in its financial and operational milestones, DPRO offers a compelling growth potential for investors seeking exposure in the aerospace and defense industry.

$AEYE ( ▲ 1.29% ) · NASDAQ Capital Market — AudioEye, Inc. 
Technology/Software - Application
YTD: -18.311%
Market Cap: $157,846,661

A leader in digital accessibility software, reported a positive shift in the latest trading session with a 2.84% increase, closing at $12.67. The company recently secured a new $20 million credit facility, underscoring strong financial health.

With the 37th consecutive period of record revenue announced for Q1 2025, AEYE appears positioned for sustained growth. Investors should note the company's robust performance in a challenging market, making it an intriguing option for technology sector exposure.

That’s it for this episode!

Thank you for taking the time to read today’s email! Your support is what allows me to send out this newsletter for free every week. 

Disclaimer: This newsletter is for informational purposes only and contains forward-looking statements that involve risks and uncertainties. Investor Insights Systems does not provide financial advice—please consult a licensed advisor before making investment decisions.